Why Satsuma investors see room for another migraine therapy

While a new class of drugs has captured most of the attention around migraine treatments, Satsuma's investors believe there's room in the marketplace for a new formulation of an old drug.

Satsuma Pharmaceuticals Inc. (South San Francisco, Calif.) said Wednesday it had raised a $62 million series B round to fund a Phase III trial of STS101, its dry powder formulation of dihydroergotamine (DHE) and intranasal delivery system, to treat acute migraine. The placebo-controlled study is to begin in 3Q19.